Published May 14, 2018
| Version v1
Poster
Open
Advances in understanding and drug development for ALK2/ACVR1 gain of function mutations in Diffuse Intrinsic Pontine Glioma (DIPG)
Creators
- 1. Structural Genomics Consortium, University of Oxford
Description
A poster outlining the program being undertaken within the Structural Genomics Consortium to co-develop drugs for both Diffuse Intrinsic Pontine Glioma (DIPG) and Fibrodysplasia Ossificans Progressiva (FOP).
The following topics are covered: prevalency of ALK2/ACVR1 mutations in DIPG, the crystal structure of the ALK2-FKBP12 complex, the increased BMP pathway activity in ALK2 mutants, the M4K Pharma ALK2 inhibitor development workflow and the M4K mission statement "Affordable Meds 4 Kids".
Notes
Files
London_CRUK_Brain_Tumour_Conference_2018_Poster.pdf
Files
(885.9 kB)
Name | Size | Download all |
---|---|---|
md5:aca6c112899e44c33522c40fb825d76d
|
885.9 kB | Preview Download |